InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation

Data ReadoutpositiveifebemtinibgarsorasibPositive

AI Analysis

Summary

InxMed announced publication of clinical results in The Lancet Oncology showing encouraging antitumor activity of ifebemtinib in combination with garsorasib for previously treated metastatic colorectal cancer harboring KRAS G12C mutations.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Encouraging antitumor activity demonstrated in publication in The Lancet Oncology

Importance:6/10

Sentiment:

0.70

Clinical DataOncologyKRAS G12CColorectal CancerPublicationCombination Therapy

Related Companies

$DFPH $CHHE

Read the original article

Published by PR Newswire Biotech on August 28, 2026 11:00 AM

Read Original